ECM-45061-69258
3 vaccinations
3 coded responses
23 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 21-25
- ZIP prefix
- 954 / CA
- Registered
- 2021-01-14
- Relationship
- Self
- Race
- White
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-01-14
Registered in v-safe
-
2021-01-14
Dose 1 — Pfizer-BioNTech
-
2021-01-14
Health check-in — day 0, dose 1Feeling: Fair · Site: Pain · Fever · Muscle or body aches, Fatigue or tiredness, Nausea, Rash, not including the immediate area around the injection site · Be unable to do your normal daily activitiesAdult check-in
-
2021-01-14
Report sent to call center — day 0, dose 1Be unable to do your normal daily activities1 call case(s)
-
2021-01-16
Health check-in — days 1–6 daily, dose 1Feeling: Good · Joint pains, Muscle or body achesAdult check-in
-
2021-01-17
Health check-in — days 1–6 daily, dose 1Feeling: Good · Joint pains, Muscle or body achesAdult check-in
- 2021-01-19
- 2021-01-21
- 2021-01-28
-
2021-02-04
Dose 2 — Pfizer-BioNTech
-
2021-02-04
Health check-in — day 0, dose 2Feeling: Fair · Site: Redness, Swelling, Itching · Muscle or body aches, Fatigue or tiredness, Abdominal pain, Rash, not including the immediate area around the injection site · Be unable to workAdult check-in
-
2021-02-05
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Swelling · Headache, Joint pains, Fatigue or tiredness, Abdominal painAdult check-in
- 2021-02-06
- 2021-02-07
- 2021-02-08
- 2021-02-10
- 2021-02-13
-
2021-02-20
Survey response — day 14, dose 2MedDRA: Chills, Dyspnoea, Headache, Pain, Pyrexia — Feeling: Good · Be unable to do your normal daily activitiesFree text: Shortness of breath, fever, headache (7/10), chills, body aches.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-25
- 2021-03-04
- 2021-03-11
- 2021-03-18
-
2021-05-06
Survey response — 3 months, dose 2MedDRA: Headache — Feeling: FairFree text: HeadachesMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-08-05
-
2022-02-04
Dose 3 — Janssen/Johnson & Johnson
-
2022-02-06
Survey response — 12 months, dose 2MedDRA: Delivery, SARS-CoV-2 test positive — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · HospitalizationFree text: Birth of child Positive covid test resultMedDRA releases: 2024-11 · check-in free text available
-
2022-02-06
Report sent to call center — 12 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prHospitalization · 1 call case(s)
-
2022-02-25
Call successfulNot applicable (accidental reporting or does not believe symptoms are related to vaccine)
- 2022-05-08
- 2022-08-05
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-14 | Pfizer-BioNTech | |
| 2 | 2021-02-04 | Pfizer-BioNTech | |
| 3 | 2022-02-04 | Janssen/Johnson & Johnson | No |
Call center
2 call center cases
1 successful · 1 priority 2/3 (triaged and no follow up)
Free text
Release 4 — day 14, dose 2
Symptoms: Shortness of breath, fever, headache (7/10), chills, body aches.
Release 8 — 3 months, dose 2
Symptoms: Headaches
Release 11 — 12 months, dose 2
Symptoms: Birth of child Positive covid test result
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Chills | ✓ | ✓ | ✓ |
| SD | Delivery | · | · | ✓ |
| SD | Dyspnoea | ✓ | ✓ | ✓ |
| SD | Headache | ✓ | ✓ | ✓ |
| SD | Pain | ✓ | ✓ | ✓ |
| SD | Pyrexia | ✓ | ✓ | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release